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Human immunodeficiency virus type 1 (HIV-1) and other retroviruses harbor short peptide motifs in Gag
that promote the release of infectious virions. These motifs, known as late assembly (L) domains, recruit a
cellular budding machinery that is required for the formation of multivesicular bodies (MVBs). The primary
L domain of HIV-1 maps to a PTAP motif in the p6 region of Gag and engages the MVB pathway by binding
to Tsg101. Additionally, HIV-1 p6 harbors an auxiliary L domain that binds to the V domain of ALIX, another
component of the MVB pathway. We now show that ALIX also binds to the nucleocapsid (NC) domain of HIV-1
Gag and that ALIX and its isolated Bro1 domain can be specifically packaged into viral particles via NC. The
interaction with ALIX depended on the zinc fingers of NC, which mediate the specific packaging of genomic
viral RNA, but was not disrupted by nuclease treatment. We also observed that HIV-1 zinc finger mutants were
defective for particle production and exhibited a similar defect in Gag processing as a PTAP deletion mutant.
The effects of the zinc finger and PTAP mutations were not additive, suggesting a functional relationship
between NC and p6. However, in contrast to the PTAP deletion mutant, the double mutants could not be
rescued by overexpressing ALIX, further supporting the notion that NC plays a role in virus release.
Retroviral Gag polyproteins harbor short peptide motifs
that promote the detachment of assembled virions from the
cell surface and from each other (16, 22, 24, 41, 49, 50, 52).
These motifs, which are known as late assembly (L) domains,
often remain functional even if moved to a different position
within Gag and can be exchanged among unrelated viruses (39,
51). In the case of human immunodeficiency virus type 1 (HIV-
1), the primary L domain consists of a conserved P(T/S)AP
motif near the beginning of the C-terminal p6 domain of the
Gag polyprotein (22, 24). The PTAP motif serves as a binding
site for the host protein Tsg101, which is required for the
release of infectious virions (21, 31, 47).
Tsg101 is a component of the endosomal sorting complex
ESCRT-I, which functions in the sorting of ubiquitinated cargo
into small vesicles that bud into the lumen of multivesicular
bodies (MVBs) (3, 23, 27). This invagination event is topolog-
ically related to retrovirus budding and ultimately serves to
deliver transmembrane proteins to lysosomal compartments
for degradation. The components of this cellular budding path-
way were initially identified in Saccharomyces cerevisiae, where
a protein network that includes at least 18 different vacuolar
protein-sorting (Vps) proteins is required for the formation of
MVBs (3). The absence of any of these gene products causes
the formation of an abnormal endosomal structure called the
class E compartment (26). The MVB sorting pathway is con-
served throughout eukaryotic evolution, and at least one ho-
molog for each of the yeast class E Vps proteins exists in
humans (48). Most of the class E Vps proteins participate in
the formation of ESCRT-I or of two other high-molecular-
weight complexes called ESCRT-II and ESCRT-III, which
function downstream of ESCRT-I (25). MVB sorting also de-
pends on the activity of the AAA-type ATPase VPS4, another
class E Vps protein that recycles the ESCRT machinery (4).
Dominant-negative versions of various ESCRT-III subunits
and of VPS4 potently inhibit the functions of all known types
of viral L domains (21, 30, 43, 44, 48, 53), indicating that all act
through components of the MVB sorting pathway.
In addition to the PTAP motif, the p6 domain of HIV-1 Gag
contains a LYPxnL motif near its C terminus that binds to
ALIX/AIP1 (44), a homolog of the yeast class E Vps protein
Bro1 that functions in endosomal trafficking (36). Like Tsg101,
ALIX promotes viral egress, which requires the separation of
the viral envelope from the plasma membrane, and is also
involved in membrane fission events that are necessary for the
completion of cytokinesis (10). ALIX has a modular organiza-
tion, with a banana-shaped N-terminal Bro1 domain, a central
domain that is shaped like a V and has therefore been termed
the V domain, and a C-terminal proline-rich domain (PRD)
that is thought to be unstructured (20, 29). ALIX interacts with
the ESCRT-III component CHMP4 through its Bro1 domain
(36), with LYPxnL-type viral L domains through its V domain
(11, 33), and with Tsg101 and other endocytic proteins through
its PRD (36).
The few lentiviruses that are known to lack a PTAP motif all
harbor a high-affinity binding site for ALIX in the C-terminal
domain of Gag (6, 44). One of these is equine infectious ane-
mia virus, which depends on ALIX for efficient virus release
(20, 30, 41, 44, 48). However, in the case of HIV-1, the ALIX
binding site in p6 has only an auxiliary role in virus release that
becomes more evident in a minimal Gag context (20, 44).
Nevertheless, exogenous ALIX can potently rescue the pro-
found budding defect of HIV-1 PTAP mutants, provided that
the ALIX binding site in p6 remains intact (20, 46).
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We previously reported that the PTAP-type L domain in
HIV-1 p6 does not function autonomously but depends on
other Gag regions in order to function (45). Our results sug-
gested that the PTAP motif needs to cooperate either with
another determinant in p6, which is now known to bind ALIX,
or with the nucleocapsid (NC)-p1 region, which immediately
precedes the p6 domain in the context of the Gag precursor
(45). The NC domain contains two highly conserved CCHC
motifs that coordinate zinc and are required for the selective
packaging of genomic viral RNA into progeny virions (5). NC
also possesses a nonspecific nucleic acid binding activity that
depends on its basic residues and is crucial for Gag polymer-
ization and assembly (13). In contrast, disruption of the two
CCHC motifs had no significant effect on Gag-Gag interac-
tions (13).
We now show that NC associates with the Bro1 domain of
ALIX through its two CCHC motifs. We also show that the
ability of ALIX to rescue a Tsg101 binding site mutant de-
pends on intact CCHC motifs in NC. Disrupting both CCHC
motifs led to defects in particle production and to an accumu-
lation of the capsid (CA)-p2 and p41 Gag cleavage intermedi-
ates that is typically seen with L domain mutants (21, 22).
However, the effects of disrupting the CCHC motifs and the
PTAP motif in p6 were not additive, which supports the hy-
pothesis that these motifs function in the same pathway during
virus production.
MATERIALS AND METHODS
Proviral constructs. HXBH10, the parental proviral plasmid used in this study,
is a vpu-positive version of the infectious HXB2 proviral clone of HIV-1.
HXBH10-gag is unable to express Gag due to premature termination codons in
the gag gene (19). The protease (PR)-negative variant HXBH10-PR, which was
used to express Pr55gag, and the HXBH10-based chimeric Gag constructs ZWT
and ZWT-p6 have been described elsewhere (1). ZWT encodes an HIV-1 Gag
precursor that has the NC-p1-p6 region precisely replaced by the GCN4 leucine
zipper domain (1). ZWT-p6 has the HIV-1 p6 coding sequence directly fused to
the 3 end of the GCN4 sequence (1). Pr55(Y36s) and ZWT-p6(Y36s) are variants
of HXBH10-PR and ZWT-p6, respectively, that harbor the previously described
Y36s mutation (22), which introduces a premature termination codon in place of
Tyr-36 of p6 without altering the pol frame. The codons for NC-p1 residues 56
to 71, 52 to 71, 36 to 71, and 15 to 71 were precisely deleted from HXBH10-Y36s
without affecting any other Gag coding sequences. This was achieved by intro-
ducing silent mutations into the first two p6 codons to generate a PstI restriction
site. All of these deletions remove the frameshift signal required for the expres-
sion of PR and thus prevent Gag processing. In contrast, the 15–39, 15–34/
C36S, 15–28, 30–31, C28,49S, and K33,34A mutations keep the frameshift signal
intact and were therefore introduced into the PR-negative version of HXBH10-
Y36s to prevent Gag processing. The 15–39, 15–34 C36S, and 15–28 mutants
have two foreign codons specifying Leu-Gln inserted in place of the deleted NC
codons. The C28,49S and 15–39 mutations were also introduced into the PR-
positive proviruses HXBH10 and PTAPP, a variant of HXBH10 with an in-
frame deletion of codons 7 through 11 of p6 (1).
Expression vectors. The pBJ5-based mammalian expression vectors for
ALIX-HA and HA-ALIX have been described previously (44). The F676D mu-
tant of ALIX-HA was made using the QuikChange mutagenesis strategy (Strat-
agene). The expression vector for HA-ALIXBro1 was obtained by inserting a
PCR product encoding ALIX residues 1 to 362 with an N-terminal hemaggluti-
nin (HA) tag between the NotI and EcoRI sites of pBJ5. The coding sequence
for APOBEC3G with a C-terminal FLAG tag was amplified from BC024268
(Open Biosystems) and cloned between the HindIII and XhoI sites of
pcDNA3.1() (Invitrogen). In all mammalian expression vectors, the start codon
is preceded by a Kozak consensus sequence for efficient translation initiation.
Analysis of virus-like particles (VLP). 293T cells (3.5  106) or HeLa cells
(8  105) were seeded into T80 flasks and cotransfected 24 h later with HIV-1
proviral DNA and ALIX expression vectors as indicated using a calcium phos-
phate precipitation technique. The total amount of transfected DNA was kept
constant with carrier DNA (pBluescript). Twenty-four h (293T) or 48 h (HeLa)
posttransfection, the cells were lysed in radioimmunoprecipitation assay buffer
(140 mM NaCl, 8 mM Na2HPO4, 2 mM NaH2PO4, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.05% sodium dodecyl sulfate [SDS]), and the culture
supernatants were clarified by low-speed centrifugation and passaged through
0.45-m filters. Virions released into the medium were then pelleted through
20% sucrose cushions. Pelletable material and the cell lysates were analyzed by
SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotting as de-
scribed elsewhere (1), using a rabbit anti-HIV CA serum (Advanced Biotech-
nologies) or the anti-HIV CA antibody 183-H12-5C (12) to detect Gag proteins.
HA-tagged ALIX was detected with the anti-HA antibody HA.11 (Covance).
GST pull-down assay. PCR fragments encoding the full-length NC (residues 1
to 55) and NC-p1 (residues 1 to 71) domains of HIV-1HXB2 Gag were inserted
in frame between the EcoRI and XhoI sites of pGEX-4T-1 (GE Healthcare).
Glutathione S-transferase (GST) fusion proteins were expressed in strain BL21
and immobilized on glutathione-Sepharose beads (GE Healthcare). The beads
were then incubated for 3 h at 4°C with hypotonic lysates of 293T cells transiently
expressing epitope-tagged ALIX or APOBEC3G, followed by extensive washing
in phosphate-buffered saline. Where indicated, the beads were incubated for
another 30 min at 37°C in the presence or absence of 75 U (0.75 U/l) benzonase
nuclease (EMD Biosciences) in benzonase buffer (1.2 mM MgCl2, 50 mM Tris-
HCl [pH 8.0]). Bound proteins were eluted by boiling in SDS-PAGE sample
buffer and resolved by SDS-PAGE. Epitope-tagged proteins were detected by
Western blotting with anti-HA or anti-FLAG M2 antibody, and GST fusion
proteins were visualized with colloidal Coomassie brilliant blue G-250.
RESULTS
NC-dependent incorporation of ALIX into HIV-1 virions.
We previously examined the incorporation of ALIX into
HIV-1 particles using the chimeric Gag constructs ZWT and
ZWT-p6 (1, 44), which have NC-p1 replaced by the GCN4
leucine zipper domain (Fig. 1A). Because the GCN4 zipper
domain rescues viral particle production by HIV-1 Gag in the
absence of the NC-p1-p6 region (1), this approach allowed us
to show that p6 mediates the specific incorporation of ALIX
(44). Consistent with this finding, we and others have shown
that both full-length ALIX and the isolated ALIX V domain
bind to an LYPxnL motif near the C terminus of HIV-1 p6 (20,
29, 33, 44, 48). We therefore expected that the incorporation of
ALIX into viral particles formed by authentic HIV-1 Gag
would be abolished by the Y36s mutation (22), which converts
the codon for Y36 of p6 into a premature termination codon
and prevents the synthesis of the LYPxnL motif. To test this
notion, we coexpressed HA-tagged ALIX with HIV-1 proviral
constructs expressing either no Gag, the wild-type (WT) Pr55
Gag polyprotein, or Pr55(Y36s) (Fig. 1A and B). As expected,
HA-ALIX was readily detected in virions produced by WT
HIV-1 Gag, and the incorporation of HA-ALIX was specific,
because its appearance in the particulate fraction depended on
the expression of Gag (Fig. 1B, lanes 1 and 2). However, we
were surprised to find that the Y36s mutation reduced the
uptake of HA-ALIX into viral particles only about twofold
(Fig. 1B, lane 3), indicating that in an otherwise-WT HIV-1
Gag context the LYPxnL motif contributes to the recruitment
of ALIX but is not essential.
To determine whether the uptake of ALIX in the absence of
the LYPxnL motif was mediated by the truncated p6 domain of
the Y36s mutant, we introduced the Y36s mutation into ZWT-p6
(Fig. 1A). As previously reported (1, 44), the ZWT chimeric
Gag molecule efficiently forms VLP that fail to incorporate
coexpressed HA-ALIX (Fig. 1C, lane 1). In contrast, HA-
ALIX was readily detectable in VLP produced by ZWT-p6 (Fig.
1C, lane 2), again consistent with previous results (44). Inter-
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estingly, in the context of ZWT-p6, the Y36s mutation abolished
the incorporation of HA-ALIX into VLP (Fig. 1C, lane 3). Of
note, the Pr55(Y36s) and ZWT-p6(Y36s) proviral constructs are
precisely identical except for the region encoding NC-p1. We
thus conclude that the ability of Pr55(Y36s) but not of ZWT-
p6(Y36s) Gag to direct the incorporation of ALIX is depen-
dent on NC-p1.
Role of NC zinc fingers in incorporation of ALIX. The NC
domain of HIV-1 Gag harbors two copies of a CCHC-type zinc
finger motif that are involved in the specific encapsidation of
genomic viral RNA into nascent viral particles. NC also exhib-
its a nonspecific RNA binding activity that depends on clusters
of basic residues and is thought to be critical for virus assembly
(8, 13). However, NC deletion mutants are not drastically
defective for viral particle production as long as the N-terminal
basic NC region proximal to the first CCHC motif is retained
(55). Furthermore, it has been shown that particle production
by a mutant that lacks nearly all of NC can be rescued by a
second site mutation that inactivates PR (38). To maintain
viral particle production, we therefore used a PR-deficient
provirus as the parental construct to generate a series of mu-
tants with in-frame deletions in the NC-p1 coding region. Fur-
thermore, all NC-p1 deletions were combined with the Y36s
mutation to eliminate the ALIX binding site in the p6 domain
of Gag (Fig. 2A).
Since Gag multimerization is concentration dependent (40),
we transfected relatively large amounts of these proviral con-
structs into 293T cells together with a vector expressing ALIX-
FIG. 1. NC-mediated incorporation of ALIX into VLP. (A) Sche-
matic illustration of the domain organizations of the HIV-1 Gag pre-
cursor (Pr55) and of mutant Gag molecules. A wavy line at the N
terminus indicates the presence of a myristylation signal, and a gray
box indicates the presence of a GCN4 zipper (Z) domain in place of
NC-p1. (B) The ALIX binding site in p6 is not essential for the
incorporation of ALIX into VLP. 293T cells were transfected with
HIV-1 proviral DNA (5 g) expressing no Gag, WT Gag, or C-termi-
nally truncated Gag, along with 5 g of a vector expressing ALIX-HA.
VLP pellets and the cell lysates were analyzed by Western blotting to
detect Gag and ALIX-HA as indicated. (C) The uptake of ALIX in the
absence of the binding site in p6 depends on NC-p1. 293T cells were
transfected with HIV-1 proviral DNAs (5 g) expressing Gag mole-
cules with a leucine zipper in place of NC-p1, along with 5 g of a
vector expressing ALIX-HA.
FIG. 2. Effects of deletions in NC-p1 on the uptake of ALIX into
VLP. (A) Schematic illustration of the Gag mutants examined. Cross-
hatched boxes indicate positions of the zinc fingers in NC. (B) p6-
independent incorporation of ALIX depends on NC but not on p1.
293T cells were transfected with the indicated amounts of mutant
HIV-1 proviral DNAs together with 3 g of a vector expressing ALIX-
HA. VLP pellets and the cell lysates were analyzed by Western blotting
to detect Gag and ALIX-HA as indicated. (C) Effects of a deletion that
removes both zinc fingers of NC together with p1.
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HA, in an effort to override potential Gag-Gag interaction
defects. As a control for Gag-independent release of ALIX in
cellular vesicles, the ALIX expression vector was cotransfected
with a provirus that lacked the ability to express Gag due to the
presence of premature termination codons in the gag gene. As
shown in Fig. 2B, deleting the region between the second
CCHC motif and p6 had no effect on particle production or on
the incorporation of ALIX-HA (lanes 3 and 4). In contrast, a
deletion which additionally removed the second CCHC motif
(36–71) reduced the incorporation of ALIX-HA at least
threefold (lane 5). Finally, ALIX-HA was no longer detectable
in the particulate fraction if the first CCHC motif was also
removed (15–71) (lane 6).
In the experiment shown in Fig. 2B, the 15–71/Y36s mutant
at 10 g produced somewhat fewer VLP than the parental
proviral construct at 5 g. Therefore, the parental construct
was titrated down to obtain equivalent levels of particle pro-
duction. We found that VLP production by the 15–71/Y36s
mutant transfected at 10 or 15 g matched or exceeded that by
the parental Y36s provirus only when less than 1 g of the
latter construct was used (Fig. 2C and data not shown). Im-
portantly, this experiment confirmed that 15–71/Y36s VLP
incorporate significantly less ALIX than Y36s VLP (Fig. 2C).
Next, we selectively targeted the CCHC motifs in NC to
determine their role in the LYPxnL-independent uptake of
ALIX. All NC mutants depicted in Fig. 3A harbored the Y36s
mutation to prevent the incorporation of ALIX via p6 and a
mutation that inactivated PR to suppress potential defects in
VLP production in the absence of NC sequences. As shown in
Fig. 3B, a deletion that removed the first CCHC motif and a
portion of the second (15–39) essentially abolished the ability
of the Y36s mutant to incorporate ALIX (compare lanes 2 and
4). A similar effect was observed when a deletion that removed
the first CCHC motif and a few flanking residues (15–34) was
combined with a point mutation that changed the second
CCHC motif to SCHC (lane 5). However, the ability to incor-
porate ALIX was partially preserved if only the first CCHC
motif was deleted and the second was kept intact (15–28)
(lane 6). We also note that the latter mutant produced more
VLP than those which retained no intact CCHC motif (Fig.
3B). To specifically examine the role of zinc-coordinating res-
idues in the incorporation of ALIX, we changed both CCHC
FIG. 3. Role of NC zinc fingers in uptake of ALIX into VLP. (A) Schematic illustration of the Gag mutants examined. Cross-hatched boxes
indicate the positions of the zinc fingers in NC, and arrowheads indicate the positions of residues that were substituted. (B) Effects of deletions
that specifically target zinc fingers. 293T cells were transfected with the indicated amounts of mutant HIV-1 proviral DNAs, together with 5 g
of a vector expressing ALIX-HA. VLP pellets and the cell lysates were analyzed by Western blotting to detect Gag and ALIX-HA as indicated.
(C) Effect of disrupting both zinc fingers through point mutations. The C28,49S/Y36s mutant was examined in duplicate to verify reproducibility.
(D) Effects of mutations in the region between the two zinc fingers.
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motifs in NC to CCHS (Fig. 3A). As shown in Fig. 3C, VLP
produced by the resulting C28,49S/Y36s mutant reproducibly
incorporated less ALIX than those produced by the parental
Y36s construct (compare lanes 1 and 2 to lanes 4 and 5). In
contrast, mutations that targeted the region between the two
CCHC motifs had no effect on the LYPxnL-independent in-
corporation of ALIX (Fig. 3D). Together, these results indi-
cate that the LYPxnL-independent uptake of ALIX is medi-
ated by the zinc fingers in NC.
ALIX physically associates with HIV-1 NC in vitro. The
packaging of ALIX into VLP in the absence of the LYPxnL
motif in p6 suggested that ALIX may also bind to other Gag
regions. To examine whether ALIX interacts with the NC-p1
region of HIV-1 Gag, GST-NC or GST-NCp1 was bound to
glutathione-Sepharose beads and incubated with extracts from
293T cells expressing FLAG- or HA-tagged ALIX. Epitope-
tagged ALIX was readily detected in association with both
GST-NC and GST-NCp1, but not with GST alone (Fig. 4A and
B). We also observed that the association of ALIX with GST-
NCp1 was considerably reduced by the C28,49S mutation (Fig.
4B), consistent with the effect of this mutation on the packag-
ing of ALIX into VLP (Fig. 3C).
We previously showed that the C28,49S double mutation,
which disrupts both CCHC motifs in NC, reduces the packag-
ing of genomic viral RNA into HIV-1 virions more than 20-
fold (18). We also showed that even the C28S change by itself
reduced the binding of viral RNA to HIV-1 Gag 10-fold in a
Northwestern blot assay (18). Since the C28,49S mutation also
significantly reduced the interaction between NC-p1 and
ALIX, we considered the possibility that the in vitro interac-
tion depended on the presence of nucleic acid. To examine this
possibility, HA-ALIX was pulled down with GST-NC-p1
bound to glutathione-Sepharose, followed by incubation of the
beads with benzonase, a promiscuous nuclease capable of de-
grading all forms of RNA and DNA. This treatment had no
effect on the association of HA-ALIX with GST-NC-p1 (Fig.
4C, lanes 1 to 4). As a control, we examined whether the
interaction between NC-p1 and APOPEC3G was affected by
benzonase. It was shown previously that the ability of Gag-
GST fusion proteins to bind APOBEC3G is inhibited by
RNase A (54). Similarly, we observed that benzonase com-
pletely disrupted the interaction between GST-NCp1 and
APOBEC3G-FLAG under the same experimental conditions
in which it had no effect on the interaction with ALIX (Fig. 4C,
lanes 5 to 7). Taken together, these results indicate that the
interaction between NC or NC-p1 and ALIX is not simply a
consequence of unspecific bridging by nucleic acids.
NC engages the Bro1 domain of ALIX. ALIX possesses an
N-terminal Bro1 domain and a central V domain that is named
for its V-like shape (20, 29). The V domain is required for the
binding of ALIX to HIV-1 p6 (44), and recent structural stud-
ies revealed that Phe-676 in a conserved hydrophobic pocket of
the V domain plays a central role in ALIX-L domain interac-
tions (20, 29). Mutating Phe-676 to Asp abolished the ability of
the isolated V domain to inhibit HIV-1 particle release (29)
and the ability of full-length ALIX to rescue viral particle
production by PTAP HIV-1 (20).
Consistent with these observations, the F676D mutation
nearly eliminated the packaging of ALIX into VLP formed by
ZWT-p6 (Fig. 5A, compare lanes 5 and 6), which depends on
the LYPxnL motif in p6 (Fig. 1C). In contrast, the same mu-
tation had only a moderate effect on the incorporation of
ALIX into particles formed by the WT Pr55 Gag polyprotein
(Fig. 5A, lanes 3 and 4). Furthermore, this effect was compa-
rable to that of removing the LYPxnL motif in p6 on the
incorporation of WT ALIX (Fig. 1B). Together, these results
suggested that the packaging of ALIX via NC does not depend
on the presence of an intact V domain.
We therefore asked whether the isolated Bro1 domain of
ALIX can be packaged into VLP. HA-ALIXBro1 was readily
detected in VLP produced by the Y36s mutant (Fig. 5B, lane
1), which expresses a Gag polyprotein that lacks the ALIX
binding site in p6 but retains the WT NC domain (Fig. 1A).
Indeed, HA-ALIXBro1 was incorporated into Y36s mutant
VLP at least as well as full-length ALIX (Fig. 5C). In marked
contrast, HA-ALIXBro1 was not at all packaged into VLP
formed by ZWT-p6 (Fig. 5B, lane 2), which lacks NC but pos-
FIG. 4. In vitro interaction between ALIX and NC or NC-p1.
(A) ALIX binds to GST-NC and GST-NC-p1. Glutathione-Sepharose
beads decorated with bacterially expressed GST or GST fusion pro-
teins were incubated with lysates from 293T cells expressing full-length
ALIX with a C-terminal FLAG tag. GST proteins bound to the beads
were detected by SDS-PAGE and Coomassie staining, and captured
ALIX was detected by Western blotting with anti-FLAG. (B) A GST
pull-down assay performed as for panel A, showing that the interaction
between ALIX and GST-NC-p1 is impaired by the C28,49S mutation,
which disrupts both CCHC motifs in NC. (C) ALIX remains bound to
GST-NCp1 in the presence of nuclease, whereas the interaction be-
tween GST-NCp1 and APOBEC3G is disrupted. GST pull-down as-
says were performed as for panel A, followed by incubation of the
beads with or without benzonase nuclease. Proteins that remained
bound to the glutathione-Sepharose beads were then detected as in-
dicated.
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sesses an intact p6 domain (Fig. 1A). This result was not
attributable to different levels of VLP production or to differ-
ences in the expression of HA-ALIXBro1 (Fig. 5B). We thus
conclude that the packaging of HA-ALIXBro1 by the Y36s
mutant is specific, and we infer that NC interacts with the Bro1
domain of ALIX.
We previously described an HIV-1 mutant which encodes a
minimal Gag protein called 8–87/126–277 that lacks the
globular domain of MA and the N-terminal domain of CA but
produces WT levels of VLP (7). L domain function in this
minimal Gag context was highly dependent on the presence of
an intact ALIX binding site in p6 (44). Moreover, VLP pro-
duction by ALIX binding site mutants could be rescued by
overexpressing ALIX (44). This activity of ALIX depended on
the presence of the PTAPP motif in p6, but not on the C-
terminal PRD of ALIX (44), which is required for the rescue
of PTAPP HIV-1 by ALIX (20, 46). Surprisingly, ALIXPRD
markedly increased VLP production even by a variant of 8–
87/126–277 that harbors the Y36s mutation and thus lacks the
entire ALIX binding site in p6 (44). We therefore examined
whether the V domain of ALIX, which binds to p6 (20, 29), is
required for the rescue of VLP production in this system. In
both 293T and HeLa cells, HA-ALIXBro1 increased VLP pro-
duction by the Y36s version of the 8–87/126–277 minimal
Gag construct more than 10-fold without affecting Gag expres-
sion levels (Fig. 6A). As expected, HA-ALIXBro1 did not in-
crease the release of PTAPP HIV-1 (Fig. 6B, lanes 1 and 2).
Furthermore, HA-ALIXBro1 did not augment virion produc-
tion by WT HIV-1 (Fig. 6B, lanes 3 and 4). Since the 8–87/
126–277/Y36s minimal Gag construct retains the NC domain,
these results raise the possibility that ALIX and the isolated
Bro1 domain can act through NC.
NC is required for the function of ALIX in HIV-1 budding.
We and Sundquist and coworkers recently reported that the
release defects of HIV-1 L domain mutants can be corrected
by increasing the cellular expression levels of ALIX (20, 46).
For instance, exogenous ALIX completely rescued particle
production by a mutant termed PTAPP, which lacks the
Tsg101 binding site in p6 (46). In this PTAPP rescue assay,
the activity of ALIX was dependent on the presence of an
intact ALIX binding site near the C terminus of p6 (20, 46).
To determine whether NC also plays a role in the rescue by
ALIX, we generated a variant of the PTAPP mutant that
harbors the C28,49S mutation in NC, which interferes with the
interaction between NC and ALIX (Fig. 3 and 4). Of note, in
a previous study the C28,49S mutation had no effect on Gag-
Gag interactions (13). Nevertheless, the C28,49S mutation by
itself reduced viral particle production in 293T cells, although
this defect was relatively mild compared to that caused by the
PTAPP mutation (Fig. 7A). The C28,49S mutation also af-
fected the pattern of cell-associated Gag proteins, which was
altered in a manner similar to that seen with the PTAPP
mutant. Specifically, both mutations altered the ratio of mature
CA versus the CA-p2 processing intermediate and caused an
accumulation of the p41 cleavage intermediate, as is typically
seen if a late assembly step is defective (21, 22). Interestingly,
the C28,49S/PTAPP double mutant was no more defective for
particle production than the original PTAPP mutant and
produced a pattern of cell-associated Gag products similar to
that seen with the two parental mutants (Fig. 7A). When an
expression vector for ALIX was cotransfected, we observed a
profound increase in viral particle production by the PTAPP
mutant (Fig. 7B), as previously described (46). In contrast,
particle production by the C28,49S/PTAPP double mutant was
only marginally improved (Fig. 7B).
We also examined the effect of the 15–39 deletion in the
PTAPP rescue assay, since the 15–39 deletion appeared to
completely prevent the recruitment of ALIX via NC (Fig. 3B).
In the presence of WT PR, the 15–39 deletion in NC caused
as profound a defect in viral particle production as the
PTAPP L domain mutation and also had a comparable effect
on the processing of cell-associated Gag (Fig. 8A, lanes 2 and
3). Remarkably, when the two mutations were combined, there
again was no additive effect on particle production or on Gag
FIG. 5. NC engages the Bro1 domain of ALIX. (A) Effect of disrupting the ligand binding pocket in the V domain on incorporation of ALIX
into VLP. 293T cells were transfected with HIV-1 proviral DNAs (7.5 g) expressing no Gag, WT Gag, or Gag with a leucine zipper in place of
NC-p1, along with 5 g of a vector expressing WT or mutant ALIX-HA. VLP pellets and the cell lysates were analyzed by Western blotting to
detect Gag and ALIX-HA as indicated. (B) NC-dependent incorporation of the isolated Bro1 domain of ALIX. 293T cells were transfected with
HIV-1 proviral DNAs (7.5 g) expressing the indicated Gag molecules, along with 5 g of a vector expressing HA-ALIXBro1. (C) NC-dependent
incorporation of full-length HA-ALIX versus that of HA-ALIXBro1. 293T cells were transfected with HIV-1 proviral DNA (7.5 g) expressing the
Pr55(Y36s) Gag precursor, along with 5 g of vector expressing HA-ALIX or HA-ALIXBro1.
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processing (Fig. 8A, lane 4). Moreover, particle production by
the double mutant could not be rescued at all by exogenous
ALIX (Fig. 8B). Taken together, these results indicate that the
determinants in NC which mediate the interaction with ALIX
also play a critical role in the function of ALIX in virus bud-
ding.
DISCUSSION
Several studies have shown that ALIX functionally interacts
with the p6 domain of HIV-1 Gag (20, 29, 33, 44, 46, 48). We
now report that ALIX also interacts with the NC-p1 region,
which precedes the p6 domain in the context of the unproc-
essed Gag polyprotein. As a consequence, the specific incor-
poration of ALIX into HIV-1 virions is only moderately af-
fected by removing its binding site in p6. While we initially
identified ALIX based on its p6-dependent incorporation into
HIV-1 VLP, this result is explained by the fact that the Gag
constructs used in our previous study had NC-p1 replaced by
the GCN4 leucine zipper (44). Indeed, the present study con-
firms that the incorporation of ALIX into VLP becomes com-
pletely dependent on the LYPxnL motif in p6 if NC-p1 is
replaced by a heterologous dimerization domain.
While the interaction with p6 is mediated by the V domain
of ALIX (20, 29, 33), the association with NC was insensitive to
FIG. 6. Effect of HA-ALIXBro1 on particle production. (A) Rescue of VLP production by a minimal Gag construct that lacks the ALIX binding
site in p6. 293T cells (lanes 1 to 4) or HeLa cells (lanes 5,6) were transfected with 1 g (lanes 1,2), 2 g (lanes 3,4), or 7.5 g (lanes 5,6) of proviral
DNA expressing the Y36s version of the 8–87/126–277 minimal Gag molecule (44), along with 2 g (lanes 1 and 2) or 5 g (lanes 3 to 6) of
empty pBJ5 or the HA-ALIXBro1 expression vector. VLP production and Gag expression levels were examined by Western blotting with anti-CA
antibody 183-H12-5C. The 8–87/126–277 minimal Gag molecule lacks the globular domain of MA and the N-terminal domain of CA, and the
Y36s truncation removes the ALIX binding site in p6. (B) HA-ALIXBro1 does not increase virion production by PTAPP or WT HIV-1. HeLa cells
were transfected with 7.5 g of PTAPP or WT HXBH10, along with 5 g of empty pBJ5 or the HA-ALIXBro1 expression vector, and virion
production was examined as above.
FIG. 7. Effects of disrupting the two NC zinc fingers on particle production and on the ability of ALIX to rescue virus release. (A) Effects of
the C28,49S mutation on particle production and Gag processing in the presence or absence of the PTAPP L domain. 293T cells were transfected
with 1 g of PR-positive HIV-1 proviral DNAs, and virion production and the pattern of cell-associated Gag products were compared by Western
blotting with anti-CA serum. (B) Effect of the C28,49S mutation on the ability of ALIX to rescue PTAPP HIV-1. 293T cells were transfected with
1 g of PR-positive HIV-1 proviral DNAs and either empty pBJ5 or a version expressing HA-ALIX (2 g).
VOL. 82, 2008 ALIX BINDS TO HIV-1 NC 1395
 at UNIV O
F M
ASS M
ED SCH on Decem






a mutation in the ligand binding pocket of the V domain that
disrupted binding to p6. Furthermore, the isolated Bro1 do-
main of ALIX was readily incorporated into viral particles in
an NC-dependent manner, indicating that ALIX associates
with NC through its N-terminal Bro1 domain. Thus, our results
imply that ALIX can interact with HIV-1 Gag through both of
its folded domains. The Bro1 domain of ALIX also interacts
with ESCRT-III component CHMP4, and mutagenic analyses
strongly suggest that this interaction is essential for the func-
tion of ALIX in virus budding (20, 46). For the interaction with
NC to be functional, ALIX would thus have to be able to
accommodate CHMP4 and NC simultaneously. In support of
this notion, the overexpression of CHMP4B had no negative
effect on the NC-dependent packaging of ALIX into HIV-1
virions (data not shown).
The two CCHC boxes in NC are thought to mediate se-
quence-specific interactions with the genomic viral RNA by
binding to exposed guanosine bases in the packaging signal (2,
15). In the present study, we found that the CCHC boxes also
mediate the packaging of ALIX into virions. In particular,
substituting zinc-coordinating residues in both CCHC boxes
simultaneously nearly abolished the LYPxnL-independent in-
corporation of ALIX and the in vitro interaction between
ALIX and NC-p1. The same modification has been shown to
cause a dramatic defect in genomic RNA packaging (18) and
to drastically reduce the incorporation of the RNA binding
protein Staufen into HIV-1 particles (32). While these paral-
lels point to a relationship between the packaging of ALIX and
of the viral genome, there is no evidence that ALIX binds
nucleic acid. Moreover, we observed that the in vitro interac-
tion between ALIX and NC-p1 was insensitive to nuclease
treatment. This finding indicates that nucleic acid is not re-
quired to maintain the interaction and that specific protein-
protein contacts are thus likely to be involved.
The interaction of NC with RNA plays an important role in
Gag multimerization and in virus assembly, apparently because
RNA is needed as a scaffold to promote Gag-Gag interactions
(9, 13, 35, 55). However, it is thought that this function of NC
involves its nonspecific RNA binding activity, which is primar-
ily mediated by basic residues and does not require intact zinc
fingers (8, 13, 14, 17, 37, 42, 55). Nevertheless, we have ob-
served that the C28,49S mutation, which disrupts both zinc
fingers and interferes with ALIX binding, reduces particle pro-
duction in HeLa cells about 10-fold (18). This observation
contrasts with the finding that the C28,49S mutation had no
effect on Gag-Gag interactions in an in vitro assay and only
moderately affected the nonspecific RNA binding activity of
NC (13). In the present study, the C28,49S mutation also re-
duced particle production in 293T cells, albeit to a lesser extent
than what we had previously observed in HeLa cells (18).
However, a deletion which affected both zinc fingers but left
the rest of NC intact reduced particle production severely.
Interestingly, these zinc finger mutations had little or no effect
on the residual ability of the PTAPP mutant to produce viral
particles, which suggests that the mutations in NC and in p6
affected the same step in virus assembly. Consistent with this
possibility, the zinc finger mutations caused a similar Gag-
processing defect as the PTAPP mutant. These observations
point to a role of HIV-1 NC in virus release, in addition to its
well-documented function in virus assembly. Of note, a func-
tion of NC in virus release is also suggested by the late budding
defect of certain NC mutants of the gammaretrovirus Moloney
murine leukemia virus (34). Moreover, budding defects strik-
ingly similar to those of L domain mutants have been observed
upon deletion of either of the two CCHC motifs in the NC
domain of an alpharetrovirus (28).
We previously presented evidence indicating that in order to
promote efficient virus release, the conserved PTAPP L do-
main core of HIV-1 needs to cooperate either with the ALIX
binding site in p6 or with NC-p1 (45). Interestingly, the release
defect of PTAPP mutants can be fully rescued by overexpress-
ing ALIX, but only if the ALIX binding site in p6 remains
intact (20, 46). In the present study, we observed that this effect
of ALIX also depended on the zinc fingers in NC, and specif-
ically on determinants in NC that mediate the interaction with
ALIX. One interpretation of these results is that the interac-
tions of ALIX with NC and with p6 are both involved in its
function in virus budding. However, it also remains possible
FIG. 8. Effects of removing the NC zinc fingers. (A) The 15–39 deletion in NC, which removes all of the first zinc finger and part of the second,
and the PTAPP deletion in p6 have comparable effects on particle production and Gag processing, and these effects are not additive. (B) The
15–39/PTAPP double mutant is not rescued by ALIX. These experiments were performed as described in the legend for Fig. 7.
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that the role of ALIX in virus release strictly depends on the
ability of NC to nucleate assembly and that zinc finger muta-
tions affect this ability in a manner that has not been readily
apparent in in vitro Gag multimerization assays (13). In either
case, the involvement of NC in the activity of ALIX supports
the notion that NC has a specific role in virus release.
ACKNOWLEDGMENTS
We thank Suman R. Das for making the APOBEC3G-FLAG ex-
pression vector and Yoshiko Usami for making the expression vector
for HA-ALIXBro1. The following reagent was obtained through the
AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH: HIV-1 p24 monoclonal antibody (183-H12-5C) from
Bruce Chesebro and Kathy Wehrly.
This work was supported by National Institutes of Health grant
AI29873.
REFERENCES
1. Accola, M. A., B. Strack, and H. G. Gottlinger. 2000. Efficient particle
production by minimal Gag constructs which retain the carboxy-terminal
domain of human immunodeficiency virus type 1 capsid-p2 and a late as-
sembly domain. J. Virol. 74:5395–5402.
2. Amarasinghe, G. K., R. N. De Guzman, R. B. Turner, K. J. Chancellor, Z. R.
Wu, and M. F. Summers. 2000. NMR structure of the HIV-1 nucleocapsid
protein bound to stem-loop SL2 of the -RNA packaging signal. Implica-
tions for genome recognition. fsJ. Mol. Biol. 301:491–511.
3. Babst, M. 2005. A protein’s final ESCRT. Traffic 6:2–9.
4. Babst, M., B. Wendland, E. J. Estepa, and S. D. Emr. 1998. The Vps4p AAA
ATPase regulates membrane association of a Vps protein complex required
for normal endosome function. EMBO J. 17:2982–2993.
5. Berkowitz, R., J. Fisher, and S. P. Goff. 1996. RNA packaging. Curr. Top.
Microbiol. Immunol. 214:177–218.
6. Bibollet-Ruche, F., E. Bailes, F. Gao, X. Pourrut, K. L. Barlow, J. P. Clewley,
J. M. Mwenda, D. K. Langat, G. K. Chege, H. M. McClure, E. Mpoudi-
Ngole, E. Delaporte, M. Peeters, G. M. Shaw, P. M. Sharp, and B. H. Hahn.
2004. New simian immunodeficiency virus infecting De Brazza’s monkeys
(Cercopithecus neglectus): evidence for a Cercopithecus monkey virus clade.
J. Virol. 78:7748–7762.
7. Borsetti, A., A. Ohagen, and H. G. Gottlinger. 1998. The C-terminal half of
the human immunodeficiency virus type 1 Gag precursor is sufficient for
efficient particle assembly. J. Virol. 72:9313–9317.
8. Bowzard, J. B., R. P. Bennett, N. K. Krishna, S. M. Ernst, A. Rein, and J. W.
Wills. 1998. Importance of basic residues in the nucleocapsid sequence for
retrovirus Gag assembly and complementation rescue. J. Virol. 72:9034–
9044.
9. Burniston, M. T., A. Cimarelli, J. Colgan, S. P. Curtis, and J. Luban. 1999.
Human immunodeficiency virus type 1 Gag polyprotein multimerization
requires the nucleocapsid domain and RNA and is promoted by the capsid-
dimer interface and the basic region of matrix protein. J. Virol. 73:8527–
8540.
10. Carlton, J. G., and J. Martin-Serrano. 2007. Parallels between cytokinesis
and retroviral budding: a role for the ESCRT machinery. Science 316:1908–
1912.
11. Chen, C., O. Vincent, J. Jin, O. A. Weisz, and R. C. Montelaro. 2005.
Functions of early (AP-2) and late (AIP1/ALIX) endocytic proteins in
equine infectious anemia virus budding. J. Biol. Chem. 280:40474–40480.
12. Chesebro, B., K. Wehrly, J. Nishio, and S. Perryman. 1992. Macrophage-
tropic human immunodeficiency virus isolates from different patients exhibit
unusual V3 envelope sequence homogeneity in comparison with T-cell-
tropic isolates: definition of critical amino acids involved in cell tropism.
J. Virol. 66:6547–6554.
13. Cimarelli, A., S. Sandin, S. Hoglund, and J. Luban. 2000. Basic residues in
human immunodeficiency virus type 1 nucleocapsid promote virion assembly
via interaction with RNA. J. Virol. 74:3046–3057.
14. Dawson, L., and X. F. Yu. 1998. The role of nucleocapsid of HIV-1 in virus
assembly. Virology 251:141–157.
15. De Guzman, R. N., Z. R. Wu, C. C. Stalling, L. Pappalardo, P. N. Borer, and
M. F. Summers. 1998. Structure of the HIV-1 nucleocapsid protein bound to
the SL3 -RNA recognition element. Science 279:384–388.
16. Demirov, D. G., J. M. Orenstein, and E. O. Freed. 2002. The late domain of
human immunodeficiency virus type 1 p6 promotes virus release in a cell
type-dependent manner. J. Virol. 76:105–117.
17. Derdowski, A., L. Ding, and P. Spearman. 2004. A novel fluorescence res-
onance energy transfer assay demonstrates that the human immunodefi-
ciency virus type 1 Pr55Gag I domain mediates Gag-Gag interactions. J. Vi-
rol. 78:1230–1242.
18. Dorfman, T., J. Luban, S. P. Goff, W. A. Haseltine, and H. G. Gottlinger.
1993. Mapping of functionally important residues of a cysteine-histidine box
in the human immunodeficiency virus type 1 nucleocapsid protein. J. Virol.
67:6159–6169.
19. Dorfman, T., F. Mammano, W. A. Haseltine, and H. G. Gottlinger. 1994.
Role of the matrix protein in the virion association of the human immuno-
deficiency virus type 1 envelope glycoprotein. J. Virol. 68:1689–1696.
20. Fisher, R. D., H. Y. Chung, Q. Zhai, H. Robinson, W. I. Sundquist, and C. P.
Hill. 2007. Structural and biochemical studies of ALIX/AIP1 and its role in
retrovirus budding. Cell 128:841–852.
21. Garrus, J. E., U. K. von Schwedler, O. W. Pornillos, S. G. Morham, K. H.
Zavitz, H. E. Wang, D. A. Wettstein, K. M. Stray, M. Cote, R. L. Rich, D. G.
Myszka, and W. I. Sundquist. 2001. Tsg101 and the vacuolar protein sorting
pathway are essential for HIV-1 budding. Cell 107:55–65.
22. Gottlinger, H. G., T. Dorfman, J. G. Sodroski, and W. A. Haseltine. 1991.
Effect of mutations affecting the p6 gag protein on human immunodeficiency
virus particle release. Proc. Natl. Acad. Sci. USA 88:3195–3199.
23. Gruenberg, J., and H. Stenmark. 2004. The biogenesis of multivesicular
endosomes. Nat. Rev. Mol. Cell Biol. 5:317–323.
24. Huang, M., J. M. Orenstein, M. A. Martin, and E. O. Freed. 1995. p6Gag is
required for particle production from full-length human immunodeficiency
virus type 1 molecular clones expressing protease. J. Virol. 69:6810–6818.
25. Hurley, J. H., and S. D. Emr. 2006. The ESCRT complexes: structure and
mechanism of a membrane-trafficking network. Annu. Rev. Biophys.
Biomol. Struct. 35:277–298.
26. Katzmann, D. J., M. Babst, and S. D. Emr. 2001. Ubiquitin-dependent
sorting into the multivesicular body pathway requires the function of a
conserved endosomal protein sorting complex, ESCRT-I. Cell 106:145–155.
27. Katzmann, D. J., G. Odorizzi, and S. D. Emr. 2002. Receptor downregula-
tion and multivesicular-body sorting. Nat. Rev. Mol. Cell Biol. 3:893–905.
28. Lee, E. G., and M. L. Linial. 2006. Deletion of a Cys-His motif from the
alpharetrovirus nucleocapsid domain reveals late domain mutant-like bud-
ding defects. Virology 347:226–233.
29. Lee, S., A. Joshi, K. Nagashima, E. O. Freed, and J. H. Hurley. 2007.
Structural basis for viral late-domain binding to Alix. Nat. Struct. Mol. Biol.
14:194–199.
30. Martin-Serrano, J., A. Yarovoy, D. Perez-Caballero, and P. D. Bieniasz.
2003. Divergent retroviral late-budding domains recruit vacuolar protein
sorting factors by using alternative adaptor proteins. Proc. Natl. Acad. Sci.
USA 100:12414–12419.
31. Martin-Serrano, J., T. Zang, and P. D. Bieniasz. 2001. HIV-1 and Ebola
virus encode small peptide motifs that recruit Tsg101 to sites of particle
assembly to facilitate egress. Nat. Med. 7:1313–1319.
32. Mouland, A. J., J. Mercier, M. Luo, L. Bernier, L. DesGroseillers, and E. A.
Cohen. 2000. The double-stranded RNA-binding protein Staufen is incor-
porated in human immunodeficiency virus type 1: evidence for a role in
genomic RNA encapsidation. J. Virol. 74:5441–5451.
33. Munshi, U. M., J. Kim, K. Nagashima, J. H. Hurley, and E. O. Freed. 2007.
An Alix fragment potently inhibits HIV-1 budding: characterization of bind-
ing to retroviral YPXL late domains. J. Biol. Chem. 282:3847–3855.
34. Muriaux, D., S. Costes, K. Nagashima, J. Mirro, E. Cho, S. Lockett, and A.
Rein. 2004. Role of murine leukemia virus nucleocapsid protein in virus
assembly. J. Virol. 78:12378–12385.
35. Muriaux, D., J. Mirro, D. Harvin, and A. Rein. 2001. RNA is a structural
element in retrovirus particles. Proc. Natl. Acad. Sci. USA 98:5246–5251.
36. Odorizzi, G. 2006. The multiple personalities of Alix. J. Cell Sci. 119:3025–
3032.
37. Ono, A., A. A. Waheed, A. Joshi, and E. O. Freed. 2005. Association of
human immunodeficiency virus type 1 Gag with membrane does not require
highly basic sequences in the nucleocapsid: use of a novel Gag multimeriza-
tion assay. J. Virol. 79:14131–14140.
38. Ott, D. E., L. V. Coren, E. N. Chertova, T. D. Gagliardi, K. Nagashima, R. C.
Sowder II, D. T. Poon, and R. J. Gorelick. 2003. Elimination of protease
activity restores efficient virion production to a human immunodeficiency
virus type 1 nucleocapsid deletion mutant. J. Virol. 77:5547–5556.
39. Parent, L. J., R. P. Bennett, R. C. Craven, T. D. Nelle, N. K. Krishna, J. B.
Bowzard, C. B. Wilson, B. A. Puffer, R. C. Montelaro, and J. W. Wills. 1995.
Positionally independent and exchangeable late budding functions of the
Rous sarcoma virus and human immunodeficiency virus Gag proteins. J. Vi-
rol. 69:5455–5460.
40. Perez-Caballero, D., T. Hatziioannou, J. Martin-Serrano, and P. D. Bieniasz.
2004. Human immunodeficiency virus type 1 matrix inhibits and confers coop-
erativity on Gag precursor-membrane interactions. J. Virol. 78:9560–9563.
41. Puffer, B. A., L. J. Parent, J. W. Wills, and R. C. Montelaro. 1997. Equine
infectious anemia virus utilizes a YXXL motif within the late assembly
domain of the Gag p9 protein. J. Virol. 71:6541–6546.
42. Sandefur, S., R. M. Smith, V. Varthakavi, and P. Spearman. 2000. Mapping
and characterization of the N-terminal I domain of human immunodefi-
ciency virus type 1 Pr55Gag. J. Virol. 74:7238–7249.
43. Shim, S., L. A. Kimpler, and P. I. Hanson. 2007. Structure/function analysis
of four core ESCRT-III proteins reveals common regulatory role for ex-
treme C-terminal domain. Traffic 8:1068–1079.
44. Strack, B., A. Calistri, S. Craig, E. Popova, and H. G. Gottlinger. 2003.
VOL. 82, 2008 ALIX BINDS TO HIV-1 NC 1397
 at UNIV O
F M
ASS M
ED SCH on Decem






AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in
virus budding. Cell 114:689–699.
45. Strack, B., A. Calistri, and H. G. Gottlinger. 2002. Late assembly domain
function can exhibit context dependence and involves ubiquitin residues
implicated in endocytosis. J. Virol. 76:5472–5479.
46. Usami, Y., S. Popov, and H. G. Gottlinger. 2007. Potent rescue of human
immunodeficiency virus type 1 late domain mutants by ALIX/AIP1 depends
on its CHMP4 binding site. J. Virol. 81:6614–6622.
47. VerPlank, L., F. Bouamr, T. J. LaGrassa, B. Agresta, A. Kikonyogo, J. Leis,
and C. A. Carter. 2001. Tsg101, a homologue of ubiquitin-conjugating (E2)
enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc. Natl. Acad. Sci.
USA 98:7724–7729.
48. von Schwedler, U. K., M. Stuchell, B. Muller, D. M. Ward, H. Y. Chung, E.
Morita, H. E. Wang, T. Davis, G. P. He, D. M. Cimbora, A. Scott, H. G.
Krausslich, J. Kaplan, S. G. Morham, and W. I. Sundquist. 2003. The
protein network of HIV budding. Cell 114:701–713.
49. Wills, J. W., C. E. Cameron, C. B. Wilson, Y. Xiang, R. P. Bennett, and J.
Leis. 1994. An assembly domain of the Rous sarcoma virus Gag protein
required late in budding. J. Virol. 68:6605–6618.
50. Yasuda, J., and E. Hunter. 1998. A proline-rich motif (PPPY) in the Gag
polyprotein of Mason-Pfizer monkey virus plays a maturation-independent
role in virion release. J. Virol. 72:4095–4103.
51. Yuan, B., S. Campbell, E. Bacharach, A. Rein, and S. P. Goff. 2000. Infec-
tivity of Moloney murine leukemia virus defective in late assembly events is
restored by late assembly domains of other retroviruses. J. Virol. 74:7250–
7260.
52. Yuan, B., X. Li, and S. P. Goff. 1999. Mutations altering the Moloney murine
leukemia virus p12 Gag protein affect virion production and early events of
the virus life cycle. EMBO J. 18:4700–4710.
53. Zamborlini, A., Y. Usami, S. R. Radoshitzky, E. Popova, G. Palu, and H.
Gottlinger. 2006. Release of autoinhibition converts ESCRT-III components
into potent inhibitors of HIV-1 budding. Proc. Natl. Acad. Sci. USA 103:
19140–19145.
54. Zennou, V., D. Perez-Caballero, H. Gottlinger, and P. D. Bieniasz. 2004.
APOBEC3G incorporation into human immunodeficiency virus type 1 par-
ticles. J. Virol. 78:12058–12061.
55. Zhang, Y., and E. Barklis. 1997. Effects of nucleocapsid mutations on human
immunodeficiency virus assembly and RNA encapsidation. J. Virol. 71:6765–
6776.
1398 POPOV ET AL. J. VIROL.
 at UNIV O
F M
ASS M
ED SCH on Decem
ber 26, 2008 
jvi.asm.org
D
ow
nloaded from
 
